Piper Jaffray Analyst: Why I Downgraded Valeant to Sell

The transcript discusses a company's shifting commentary on its business segments, highlighting weaknesses in traditionally strong areas like Gastroenterology and Western Europe. It notes changes in growth strategies, with dermatology no longer a key focus. The potential impact of a partnership with Walgreens is explored, emphasizing uncertainty in future growth and the role of pricing strategies.

Which segments of the company, previously considered strong, are now under pressure?

• Technology and South America

• Gastroenterology and Western Europe

• Dermatology and North America

• Pharmaceuticals and Asia

What significant change in the company's growth strategy was noted since December?

• Expansion into new geographical markets

• Dermatology is no longer a key growth driver

• Increased focus on technology

• Reduction in workforce

What is the potential benefit of the Walgreens partnership for the company?

• Potential volume growth

• Guaranteed price growth

• Immediate increase in profits

• Expansion into new markets

What has been a major component of the company's growth in previous quarters?

• Market expansion

• New product launches

• Price growth

• Volume growth

What is the current challenge in predicting the company's future growth?

• Lack of new products

• Uncertainty in the Walgreens partnership impact

• Decreasing market share

• High employee turnover